A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose, Dose Escalation Study to Evaluate the Efficacy, Safety and Tolerability of NKTR-118 in Patients With Opioid-Induced Constipation (OIC)
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Naloxegol (Primary)
- Indications Constipation
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 19 Sep 2012 New source identified an integrated: European Clinical Trials Database record (EudraCT2007-005421-30).
- 21 Aug 2012 New trial record